Global Cancer Oncology Testing 麻豆原创 Research Report 2024

Publication ID:

PB507241814

Publication Date:

July 10, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Cancer Oncology Testing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Cancer Oncology Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Oncology Testing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Cancer Oncology Testing in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Cancer Oncology Testing include Devyser, Agendia, Illumina, Personal Genome Diagnostics, Veracyte, Pacific Biosciences of California, Qiagen, Agilent Technologies and Natera, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Cancer Oncology Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Oncology Testing.
Report Scope
The Cancer Oncology Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cancer Oncology Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Oncology Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Devyser
Agendia
Illumina
Personal Genome Diagnostics
Veracyte
Pacific Biosciences of California
Qiagen
Agilent Technologies
Natera
Bio Rad Laboratories
Myriad Genetics
Segment by Type
Fluorescence In Situ Hybridization
Polymerase Chain Reaction
Microarray Technology
Serum Proteomics
Nucleic Acid Sequencing
Segment by Application
Hospitals
Speciality Clinics
Research Institutes
Diagnostics Laboratories
Biopharmaceutical Companies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Oncology Testing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Cancer Oncology Testing 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Fluorescence In Situ Hybridization
1.2.3 Polymerase Chain Reaction
1.2.4 Microarray Technology
1.2.5 Serum Proteomics
1.2.6 Nucleic Acid Sequencing
1.3 麻豆原创 by Application
1.3.1 Global Cancer Oncology Testing 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Speciality Clinics
1.3.4 Research Institutes
1.3.5 Diagnostics Laboratories
1.3.6 Biopharmaceutical Companies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Oncology Testing 麻豆原创 Perspective (2019-2030)
2.2 Cancer Oncology Testing Growth Trends by Region
2.2.1 Global Cancer Oncology Testing 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cancer Oncology Testing Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Cancer Oncology Testing Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Cancer Oncology Testing 麻豆原创 Dynamics
2.3.1 Cancer Oncology Testing Industry Trends
2.3.2 Cancer Oncology Testing 麻豆原创 Drivers
2.3.3 Cancer Oncology Testing 麻豆原创 Challenges
2.3.4 Cancer Oncology Testing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Oncology Testing Players by Revenue
3.1.1 Global Top Cancer Oncology Testing Players by Revenue (2019-2024)
3.1.2 Global Cancer Oncology Testing Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Cancer Oncology Testing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Oncology Testing Revenue
3.4 Global Cancer Oncology Testing 麻豆原创 Concentration Ratio
3.4.1 Global Cancer Oncology Testing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Oncology Testing Revenue in 2023
3.5 Cancer Oncology Testing Key Players Head office and Area Served
3.6 Key Players Cancer Oncology Testing Product Solution and Service
3.7 Date of Enter into Cancer Oncology Testing 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Oncology Testing Breakdown Data by Type
4.1 Global Cancer Oncology Testing Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Cancer Oncology Testing Forecasted 麻豆原创 Size by Type (2025-2030)
5 Cancer Oncology Testing Breakdown Data by Application
5.1 Global Cancer Oncology Testing Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Cancer Oncology Testing Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Cancer Oncology Testing 麻豆原创 Size (2019-2030)
6.2 North America Cancer Oncology Testing 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cancer Oncology Testing 麻豆原创 Size by Country (2019-2024)
6.4 North America Cancer Oncology Testing 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Oncology Testing 麻豆原创 Size (2019-2030)
7.2 Europe Cancer Oncology Testing 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cancer Oncology Testing 麻豆原创 Size by Country (2019-2024)
7.4 Europe Cancer Oncology Testing 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Oncology Testing 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Cancer Oncology Testing 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cancer Oncology Testing 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Cancer Oncology Testing 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Oncology Testing 麻豆原创 Size (2019-2030)
9.2 Latin America Cancer Oncology Testing 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cancer Oncology Testing 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Cancer Oncology Testing 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Oncology Testing 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Cancer Oncology Testing 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cancer Oncology Testing 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Cancer Oncology Testing 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Devyser
11.1.1 Devyser Company Detail
11.1.2 Devyser Business Overview
11.1.3 Devyser Cancer Oncology Testing Introduction
11.1.4 Devyser Revenue in Cancer Oncology Testing Business (2019-2024)
11.1.5 Devyser Recent Development
11.2 Agendia
11.2.1 Agendia Company Detail
11.2.2 Agendia Business Overview
11.2.3 Agendia Cancer Oncology Testing Introduction
11.2.4 Agendia Revenue in Cancer Oncology Testing Business (2019-2024)
11.2.5 Agendia Recent Development
11.3 Illumina
11.3.1 Illumina Company Detail
11.3.2 Illumina Business Overview
11.3.3 Illumina Cancer Oncology Testing Introduction
11.3.4 Illumina Revenue in Cancer Oncology Testing Business (2019-2024)
11.3.5 Illumina Recent Development
11.4 Personal Genome Diagnostics
11.4.1 Personal Genome Diagnostics Company Detail
11.4.2 Personal Genome Diagnostics Business Overview
11.4.3 Personal Genome Diagnostics Cancer Oncology Testing Introduction
11.4.4 Personal Genome Diagnostics Revenue in Cancer Oncology Testing Business (2019-2024)
11.4.5 Personal Genome Diagnostics Recent Development
11.5 Veracyte
11.5.1 Veracyte Company Detail
11.5.2 Veracyte Business Overview
11.5.3 Veracyte Cancer Oncology Testing Introduction
11.5.4 Veracyte Revenue in Cancer Oncology Testing Business (2019-2024)
11.5.5 Veracyte Recent Development
11.6 Pacific Biosciences of California
11.6.1 Pacific Biosciences of California Company Detail
11.6.2 Pacific Biosciences of California Business Overview
11.6.3 Pacific Biosciences of California Cancer Oncology Testing Introduction
11.6.4 Pacific Biosciences of California Revenue in Cancer Oncology Testing Business (2019-2024)
11.6.5 Pacific Biosciences of California Recent Development
11.7 Qiagen
11.7.1 Qiagen Company Detail
11.7.2 Qiagen Business Overview
11.7.3 Qiagen Cancer Oncology Testing Introduction
11.7.4 Qiagen Revenue in Cancer Oncology Testing Business (2019-2024)
11.7.5 Qiagen Recent Development
11.8 Agilent Technologies
11.8.1 Agilent Technologies Company Detail
11.8.2 Agilent Technologies Business Overview
11.8.3 Agilent Technologies Cancer Oncology Testing Introduction
11.8.4 Agilent Technologies Revenue in Cancer Oncology Testing Business (2019-2024)
11.8.5 Agilent Technologies Recent Development
11.9 Natera
11.9.1 Natera Company Detail
11.9.2 Natera Business Overview
11.9.3 Natera Cancer Oncology Testing Introduction
11.9.4 Natera Revenue in Cancer Oncology Testing Business (2019-2024)
11.9.5 Natera Recent Development
11.10 Bio Rad Laboratories
11.10.1 Bio Rad Laboratories Company Detail
11.10.2 Bio Rad Laboratories Business Overview
11.10.3 Bio Rad Laboratories Cancer Oncology Testing Introduction
11.10.4 Bio Rad Laboratories Revenue in Cancer Oncology Testing Business (2019-2024)
11.10.5 Bio Rad Laboratories Recent Development
11.11 Myriad Genetics
11.11.1 Myriad Genetics Company Detail
11.11.2 Myriad Genetics Business Overview
11.11.3 Myriad Genetics Cancer Oncology Testing Introduction
11.11.4 Myriad Genetics Revenue in Cancer Oncology Testing Business (2019-2024)
11.11.5 Myriad Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Devyser
Agendia
Illumina
Personal Genome Diagnostics
Veracyte
Pacific Biosciences of California
Qiagen
Agilent Technologies
Natera
Bio Rad Laboratories
Myriad Genetics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.